Literature DB >> 11369825

Sympathetic overactivity and arterial hypertension in renal failure.

S R Orth1, K Amann, K Strojek, E Ritz.   

Abstract

In the past, it had been presumed that hypertension in chronic renal disease can be explained by the dual effects of sodium retention and inappropriate activity of the renin-angiotensin system. Recent experimental and clinical data provide strong evidence that the increase in blood pressure is to a large part due to sympathetic overactivity which is triggered by afferent signals emanating from the kidney and resetting sympathetic tone by stimulation of hypothalamic centres. The sequelae of sympathetic overactivity extend beyond their effects on blood pressure and include accelerated progression of renal failure and presumably increased cardiac arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369825     DOI: 10.1093/ndt/16.suppl_1.67

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  12 in total

Review 1.  Purinergic signalling in the kidney in health and disease.

Authors:  Geoffrey Burnstock; Louise C Evans; Matthew A Bailey
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

3.  Left ventricular mass and heart sympathetic activity after renal transplantation in children and young adults.

Authors:  Juan Manuel Guízar-Mendoza; Norma Amador-Licona; Efrén Edgard Lozada; Leticia Rodriguez; María Gutiérrez-Navarro; Luis Antonio Dubey-Ortega; José Trejo-Bellido; José de Jesús Encarnación; María De la Cruz Ruiz-Jaramillo
Journal:  Pediatr Nephrol       Date:  2006-08-15       Impact factor: 3.714

4.  End Stage Renal Disease: Not a Contraindication for Minor Oral Surgery-Protocol for the Management of Oral Surgery patients with ESRD on Hemodialysis.

Authors:  Sneha Pendem; G Lakshmi Narayana; Poornima Ravi
Journal:  J Maxillofac Oral Surg       Date:  2016-07-28

5.  Chromogranin A polymorphisms are associated with hypertensive renal disease.

Authors:  Rany M Salem; Peter E Cadman; Yuqing Chen; Fangwen Rao; Gen Wen; Bruce A Hamilton; Brinda K Rana; Douglas W Smith; Mats Stridsberg; Harry J Ward; Manjula Mahata; Sushi K Mahata; Donald W Bowden; Pamela J Hicks; Barry I Freedman; Nicholas J Schork; Daniel T O'Connor
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

Review 6.  The management of diabetic neuropathy in CKD.

Authors:  Rodica Pop-Busui; Laurel Roberts; Subramaniam Pennathur; Mathias Kretzler; Frank C Brosius; Eva L Feldman
Journal:  Am J Kidney Dis       Date:  2009-12-30       Impact factor: 8.860

7.  L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.

Authors:  Tomohiko Kanaoka; Kouichi Tamura; Hiromichi Wakui; Masato Ohsawa; Kengo Azushima; Kazushi Uneda; Ryu Kobayashi; Tetsuya Fujikawa; Yuko Tsurumi-Ikeya; Akinobu Maeda; Mai Yanagi; Yoshiyuki Toya; Satoshi Umemura
Journal:  Int J Mol Sci       Date:  2013-08-16       Impact factor: 5.923

8.  The molecular mechanism of leptin secretion and expression induced by aristolochic acid in kidney fibroblast.

Authors:  Tsung-Chieh Lin; Tien-Chiang Lee; Shih-Lan Hsu; Chung-Shi Yang
Journal:  PLoS One       Date:  2011-02-03       Impact factor: 3.240

9.  Neuronal activation in the central nervous system of rats in the initial stage of chronic kidney disease-modulatory effects of losartan and moxonidine.

Authors:  Miklós Palkovits; Katarína Šebeková; Kristina Simon Klenovics; Anton Kebis; Gholamreza Fazeli; Udo Bahner; August Heidland
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

Review 10.  [Sympathetic overactivity and the kidney].

Authors:  Antje Habicht; Bruno Watschinger
Journal:  Wien Klin Wochenschr       Date:  2003-09-30       Impact factor: 2.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.